Glyconjugate Vaccines
US-2024382585-A1 · Nov 21, 2024 · US
D-amino acid derivative-modified peptidoglycan and methods of use thereof
US9789180B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9789180-B2 |
| Application number | US-201615087348-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 31, 2016 |
| Priority date | Nov 30, 2012 |
| Publication date | Oct 17, 2017 |
| Grant date | Oct 17, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides modified bacteria and modified peptidoglycan comprising modified D-amino acids; compositions comprising the modified bacteria or peptidoglycan; and methods of using the modified bacteria or peptidoglycan. The modified D-amino acids include a bioorthogonal functional group such as an azide, an alkyne or a norbornene group. Also provided are modified peptidoglycans conjugated to a molecule of interest via a linker.
First claim
Opening claim text (preview).
What is claimed is: 1. A modified bacterial cell comprising a modified peptidoglycan, wherein the modified peptidoglycan comprises at least one modified D-amino acid, wherein the at least one modified D-amino acid is an azide-modified, an alkyne-modified, or a norbornene-modified D-amino acid. 2. The modified bacterial cell of claim 1 , wherein the bacterial cell is present intracellularly in a eukaryotic host cell. 3. The modified bacterial cell of claim 2 , wherein the eukaryotic host cell is a macrophage. 4. The modified bacterial cell of claim 1 , wherein the modified D-amino acid is an azide-modified D-amino acid. 5. The modified bacterial cell of claim 1 , wherein the modified D-amino acid is an alkyne-modified D-amino acid. 6. The modified bacterial cell of claim 4 , wherein the modified D-amino acid is a norbornene-modified D-amino acid. 7. A modified bacterial cell comprising a modified peptidoglycan, wherein the modified peptidoglycan comprises at least one modified D-amino acid conjugated to a reagent via a heterocycle, wherein the at least one modified D-amino acid is an azide-modified, an alkyne-modified, or a norbornene-modified D-amino acid, and the reagent is an azide-containing reagent, an alkynyl reagent or a norbornene-reactive reagent. 8. The modified bacterial cell of claim 7 , wherein the bacterial cell is present intracellularly in a eukaryotic host cell. 9. The modified bacterial cell of claim 7 , wherein the eukaryotic host cell is a macrophage. 10. The modified bacterial cell of claim 7 , wherein the reagent comprises a detectable label. 11. The modified bacterial cell of claim 10 , wherein the detectable label is a fluorescent label. 12. The modified bacterial cell of claim 10 , wherein the detectable label is a radioactive isotope. 13. The modified bacterial cell of claim 10 , wherein the detectable label is biotin. 14. The modified bacterial cell of claim 10 , wherein the detectable label is a peptide that can be detected by antibody binding. 15. The modified bacterial cell of claim 7 , wherein the reagent comprises a therapeutic agent. 16. The modified bacterial cell of claim 7 , wherein the reagent comprises an immunomodulatory molecule. 17. The modified bacterial cell of claim 7 , wherein the modified D-amino acid is an azide-modified D-amino acid, and the reagent is an alkynyl or phosphine reagent. 18. The modified bacterial cell of claim 7 , wherein the modified D-amino acid is an alkyne-modified D-amino acid, and the reagent is an azide or alkynyl reagent. 19. The modified bacterial cell of claim 7 , wherein the modified D-amino acid is a norbornene-modified D-amino acid, and the reagent is a norbornene-reactive agent.
Assignees
Inventors
Classifications
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title
- A61K39/385Primary
Haptens or antigens, bound to carriers · CPC title
Other bacterial proteins, e.g. OMP · CPC title
the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines · CPC title
Proteoglycans, e.g. aggreccan · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9789180B2 cover?
- The present disclosure provides modified bacteria and modified peptidoglycan comprising modified D-amino acids; compositions comprising the modified bacteria or peptidoglycan; and methods of using the modified bacteria or peptidoglycan. The modified D-amino acids include a bioorthogonal functional group such as an azide, an alkyne or a norbornene group. Also provided are modified peptidoglycans…
- Who is the assignee on this patent?
- Univ California
- What technology area does this patent fall under?
- Primary CPC classification A61K39/385. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).